+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

North America RNAi Therapeutics Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Molecule Type and MicroRNA; Application; Route of Administration; and End User and Country

  • ID: 5204860
  • Report
  • October 2020
  • Region: North America
  • 123 pages
  • The Insight Partners
UP TO OFF
until Jan 31st 2021

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Arbutus Biopharma
  • Quark
Small Interfering RNAs (siRNA) Molecule Type Segment Held Largest Share of RNAi Therapeutics in 2019

According to the new market research study on “North America RNAi Therapeutics Market to 2027 - Regional Analysis and Forecast - by Molecule Type, Route of Administration, Application, and End User” the North America RNAi therapeutics market is expected to reach US$598.60 million in 2027 from US$302.77 million in 2019, it is estimated to grow with a CAGR of 9.0% from 2020-2027. The report provides trends prevailing in the North America RNAi therapeutics market and the factors driving the market growth along with those hindering it.

In 2019, the small interfering RNAs (siRNA) accounted for the highest share of the market. Growth of this segment is attributed to the increasing preference for small interfering RNAs for drug development and growing number of research partnerships. Furthermore, MicroRNA (miRNA) segment is expected to register higher CAGR in the RNAi therapeutics market during the forecast period.

The growth of the North America RNAi therapeutics market is mainly attributed to growing prevalence of chronic conditions and rising investments for development of RNAi therapeutics. Additionally, increasing awareness about RNAi therapies and its benefits are anticipated to boost the research and innovations of RNAi therapeutics in the region will eventually drive the market growth. However, the high cost of RNAi therapy development is the major factor hindering the market growth in North America.

Alnylam Pharmaceuticals, Inc; Arrowhead Pharmaceuticals, Inc; Quark; Rexahn Pharmaceuticals, Inc; and Arbutus Biopharma are among the leading companies operating in the North America RNAi therapeutics market.

The Report Segments North America RNAi Therapeutics Market as Follows:

By Molecule Type
  • Small Interfering RNAs (siRNA)
  • MicroRNA (miRNA)
By Route of Administration
  • Pulmonary Delivery
  • Intravenous Injections
  • Intradermal Injections
  • Intraperitoneal Injections
  • Others
By Application
  • Oncology
  • Cardiovascular
  • Respiratory Disorders
  • Renal Diseases
  • Genetic Disorders
  • Neurodegenerative Disorders
  • Infectious Diseases
  • Others
By End User
  • Research and Academic Laboratories
  • Hospitals
  • Diagnostic Laboratories
By Country
  • US
  • Canada
  • Mexico
Reasons to Buy
  • It provides an understanding of the North America, RNAi therapeutics market landscape and identifies RNAi therapeutics market segments that are most likely to guarantee a strong return.
  • Stay ahead of the race by comprehending the ever-changing competitive landscape for the North America RNAi therapeutics market.
  • It helps efficiently plan merger and acquisition, and partnership deals in the RNAi therapeutics market by identifying market segments with the most promising probable sales
  • It facilitates knowledgeable business decision-making through perceptive and comprehensive analysis of RNAi therapeutics market performance of various segments pertaining to the North America RNAi therapeutics market.
  • It provides RNAi therapeutics market revenue forecast of the market based on various segments for the period from 2019 to 2027.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Arbutus Biopharma
  • Quark
1. Introduction
1.1 Scope of the Study
1.2 Research Report Guidance
1.3 Market Segmentation
1.3.1 North America RNAi Therapeutics Market - By Molecule Type
1.3.2 North America RNAi Therapeutics Market - By Application
1.3.3 North America RNAi Therapeutics Market - By Route of Administration
1.3.4 North America RNAi Therapeutics Market- By End User
1.3.5 North America RNAi Therapeutics Market - By Country

2. North America RNAi Therapeutics Market - Key Takeaways

3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. North America RNAi Therapeutics Market - Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 RNAi therapeutics Market - North America PEST Analysis
4.3 Expert Opinion

5. North America RNAi Therapeutics Market - Key Market Dynamics
5.1 Key Market Drivers
5.1.1 Growing Investments in RNAi Therapies
5.1.2 Rising Prevalence of Chronic Conditions and Infectious Diseases
5.2 Market Restraints
5.2.1 High Cost for RNAi Therapy Development
5.3 Market Opportunities
5.3.1 Significant Number of Pipeline Candidates for Strategic Alliances
5.4 Future Trends
5.4.1 Rising Emphasis on RNA Technologies
5.5 Impact analysis

6. RNAi Therapeutics Market - North America Analysis
6.1 North America RNAi Therapeutics Market Revenue Forecasts and Analysis

7. North America RNAi Therapeutics Market Analysis and Forecasts To 2027 - By Molecule Type
7.1 Overview
7.2 North America RNAi Therapeutics Market, By Molecule Type 2019 & 2027 (%)
7.2.1 North America RNAi therapeutics Market Revenue and Forecasts to 2027, By Molecule Type (US$ Mn)
7.3 Small Interfering RNAs (siRNA)
7.3.1 Overview
7.3.2 North America Small Interfering RNAs (siRNA) Market Revenue and Forecast to 2027 (US$ Mn)
7.4 MicroRNA (miRNA)
7.4.1 Overview
7.4.2 North America MicroRNA (miRNA) Market Revenue and Forecasts to 2027 (US$ Mn)

8. North America RNAi therapeutics Market Analysis and Forecasts To 2027 - By Application
8.1 Overview
8.2 North America RNAi therapeutics Market, By Application 2019 & 2027 (%)
8.2.1 North America RNAi therapeutics Market Revenue and Forecasts to 2027, By Application (US$ Mn)
8.3 Genetic Disorders
8.3.1 Overview
8.3.2 North America Genetic Disorders Market Revenue and Forecast to 2027 (US$ Mn)
8.4 Oncology
8.4.1 Overview
8.4.2 North America Oncology Market Revenue and Forecasts to 2027 (US$ Mn)
8.5 Neurodegenerative Disorders
8.5.1 Overview
8.5.2 North America Neurodegenerative Disorders Market Revenue and Forecasts to 2027 (US$ Mn)
8.6 Cardiovascular Disorders
8.6.1 Overview
8.6.2 North America Cardiovascular Disorders Market Revenue and Forecasts to 2027 (US$ Mn)
8.7 Respiratory Disorders
8.7.1 Overview
8.7.2 North America Respiratory Disorders Market Revenue and Forecasts to 2027 (US$ Mn)
8.8 Infectious Diseases
8.8.1 Overview
8.8.2 North America Infectious Diseases Market Revenue and Forecasts to 2027 (US$ Mn)
8.9 Renal Diseases
8.9.1 Overview
8.9.2 North America Renal Diseases Market Revenue and Forecasts to 2027 (US$ Mn)
8.10 Other Disorders
8.10.1 Overview
8.10.2 North America Other Disorders Market Revenue and Forecasts to 2027 (US$ Mn)

9. North America RNAi therapeutics Market Analysis and Forecasts To 2027 - By Route of Administration
9.1 Overview
9.2 North America RNAi therapeutics Market, By Route of Administration 2019 & 2027 (%)
9.2.1 North America RNAi therapeutics Market Revenue and Forecasts to 2027, By Route of Administration (US$ Mn)
9.3 Intradermal Injections
9.3.1 Overview
9.3.2 North America Intradermal Injections Market Revenue and Forecast to 2027 (US$ Mn)
9.4 Pulmonary Delivery
9.4.1 Overview
9.4.2 North America Pulmonary Delivery Market Revenue and Forecasts to 2027 (US$ Mn)
9.5 Intravenous Injections
9.5.1 Overview
9.5.2 North America Intravenous Injections Market Revenue and Forecasts to 2027 (US$ Mn)
9.6 Intraperitoneal Injections
9.6.1 Overview
9.6.2 North America Intraperitoneal Injections Market Revenue and Forecasts to 2027 (US$ Mn)
9.7 Other Route of Administrations
9.7.1 Overview
9.7.2 North America Other Route of Administrations Market Revenue and Forecasts to 2027 (US$ Mn)

10. North America RNAi Therapeutics Market Analysis - By End-User
10.1 Overview
10.2 North America RNAi Therapeutics Market, By End-User 2019-2027 (%)
10.2.1 North America RNAi Therapeutics Market Revenue and Forecasts to 2027, By End-User (US$ Mn)
10.3 Diagnostic Laboratories
10.3.1 Overview
10.3.2 North America Diagnostic Laboratories Market Revenue and Forecasts to 2027 (US$ Mn)
10.4 Research and Academic Laboratories
10.4.1 Overview
10.4.2 North America Research and Academic Laboratories Market Revenue and Forecasts to 2027 (US$ Mn)
10.5 Hospitals
10.5.1 Overview
10.5.2 North America Hospitals Market Revenue and Forecasts to 2027 (US$ Mn)

11. RNAi therapeutics Market Revenue and Forecasts To 2027 - Geographical Analysis
11.1 North America: RNAi Therapeutics Market
11.1.1 Overview
11.1.2 North America: RNAi Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
11.1.3 North America: RNAi Therapeutics Market, by Molecule Type, 2018-2027 (USD Million)
11.1.4 North America: RNAi Therapeutics Market, by Application, 2018-2027 (USD Million)
11.1.5 North America: RNAi Therapeutics Market, by Route of Administration, 2018-2027 (USD Million)
11.1.6 North America: RNAi Therapeutics Market, by End User, 2018-2027 (USD Million)
11.1.7 North America: RNAi Therapeutics Market, by Country, 2019 & 2027 (%)
11.1.8 US: RNAi Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
11.1.8.1 US: RNAi Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
11.1.8.2 US: RNAi Therapeutics Market, by Molecule Type, 2018-2027 (USD Million)
11.1.8.3 US: RNAi Therapeutics Market, by Application, 2018-2027 (USD Million)
11.1.8.4 US: RNAi Therapeutics Market, by Route of Administration, 2018-2027 (USD Million)
11.1.8.5 US: RNAi Therapeutics Market, by End User, 2018-2027 (USD Million)
11.1.9 Canada: RNAi Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
11.1.9.1 Canada: RNAi Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
11.1.9.2 Canada: RNAi Therapeutics Market, by Molecule Type, 2018-2027 (USD Million)
11.1.9.3 Canada RNAi Therapeutics Market, by Application, 2018-2027 (USD Million)
11.1.9.4 Canada: RNAi Therapeutics Market, by Route of Administration, 2018-2027 (USD Million)
11.1.9.5 Canada: RNAi Therapeutics Market, by End User, 2018-2027 (USD Million)
11.1.10 Mexico: RNAi Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
11.1.10.1 Mexico: RNAi Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
11.1.10.2 Mexico: RNAi Therapeutics Market, by Molecule Type, 2018-2027 (USD Million)
11.1.10.3 Mexico: RNAi Therapeutics Market, by Application, 2018-2027 (USD Million)
11.1.10.4 Mexico: RNAi Therapeutics Market, by Route of Administration, 2018-2027 (USD Million)
11.1.10.5 Mexico: RNAi Therapeutics Market, by End User, 2018-2027 (USD Million)

12. Impact of COVID-19 Pandemic on North America RNAi therapeutics Market
12.1 North America: Impact Assessment of COVID-19 Pandemic

13. Company Profiles
13.1 Alnylam Pharmaceuticals, Inc.
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Arrowhead Pharmaceuticals, Inc
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Quark
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Rexahn Pharmaceuticals, Inc
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Arbutus Biopharma
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments

14. Appendix
14.1 About the Publisher
14.2 Glossary of Terms

List of Tables
Table 1. North America RNAi therapeutics Market Revenue and Forecasts To 2027, By Molecule Type (US$ Mn)
Table 2. North America RNAi therapeutics Market Revenue and Forecasts To 2027, By Application (US$ Mn)
Table 3. North America RNAi therapeutics Market Revenue and Forecasts To 2027, By Route of Administration (US$ Mn)
Table 4. North America RNAi Therapeutics Market Revenue and Forecasts To 2027, By End-User (US$ Mn)
Table 5. North America RNAi Therapeutics Market, by Molecule Type- Revenue and Forecast to 2027 (USD Million)
Table 6. North America RNAi Therapeutics Market, by Application - Revenue and Forecast to 2027 (USD Million)
Table 7. North America RNAi Therapeutics Market, by Route of Administration - Revenue and Forecast to 2027 (USD Million)
Table 8. North America RNAi Therapeutics Market, by End User - Revenue and Forecast to 2027 (USD Million)
Table 9. US RNAi Therapeutics Market, by Molecule Type - Revenue and Forecast to 2027 (USD Million)
Table 10. US RNAi Therapeutics Market, by Application - Revenue and Forecast to 2027 (USD Million)
Table 11. US RNAi Therapeutics Market, by Route of Administration - Revenue and Forecast to 2027 (USD Million)
Table 12. US RNAi Therapeutics Market, by End User - Revenue and Forecast to 2027 (USD Million)
Table 13. Canada RNAi Therapeutics Market, by Molecule Type - Revenue and Forecast to 2027 (USD Million)
Table 14. Canada RNAi Therapeutics Market, by Application - Revenue and Forecast to 2027 (USD Million)
Table 15. Canada RNAi Therapeutics Market, by Route of Administration - Revenue and Forecast to 2027 (USD Million)
Table 16. Canada RNAi Therapeutics Market, by End User - Revenue and Forecast to 2027 (USD Million)
Table 17. Mexico RNAi Therapeutics Market, by Molecule Type - Revenue and Forecast to 2027 (USD Million)
Table 18. Mexico RNAi Therapeutics Market, by Application - Revenue and Forecast to 2027 (USD Million)
Table 19. Mexico RNAi Therapeutics Market, by Route of Administration - Revenue and Forecast to 2027 (USD Million)
Table 20. Mexico RNAi Therapeutics Market, by End User - Revenue and Forecast to 2027 (USD Million)
Table 21. Glossary of Terms, RNAi Therapeutics Market

List of Figures
Figure 1. RNAi Therapeutics Market Segmentation
Figure 2. North America RNAi Therapeutics Market Overview
Figure 3. Small Interfering RNAs (siRNA) Molecule Type Segment Held Largest Share of RNAi Therapeutics Market
Figure 4. US is Expected to Show Remarkable Growth During the Forecast Period
Figure 5. North America RNAi Therapeutics Market - Leading Country Markets (US$ Mn)
Figure 6. RNAi Therapeutics Market - North America PEST Analysis
Figure 7. RNAi Therapeutics Market Impact Analysis of Driver and Restraints
Figure 8. North America RNAi Therapeutics Market - Revenue Forecasts and Analysis - 2019-2027
Figure 9. North America RNAi Therapeutics Market, By Molecule Type 2019 & 2027 (%)
Figure 10. North America Small Interfering RNAs (siRNA) Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 11. North America MicroRNA (miRNA) Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 12. North America RNAi therapeutics Market, By Application 2019 & 2027 (%)
Figure 13. North America Genetic Disorders Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 14. North America Oncology Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 15. North America Neurodegenerative Disorders Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 16. North America Cardiovascular Disorders Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 17. North America Respiratory Disorders Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 18. North America Infectious Diseases Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 19. North America Renal Diseases Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 20. North America Other Disorders Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 21. North America RNAi therapeutics Market, By Route of Administration 2019 & 2027 (%)
Figure 22. North America Intradermal Injections Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 23. North America Pulmonary Delivery Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 24. North America Intravenous Injections Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 25. North America Intraperitoneal Injections Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 26. North America Other Route of Administrations Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 27. North America RNAi Therapeutics Market, by End-User 2019 & 2027 (%)
Figure 28. North America Diagnostic Laboratories Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 29. North America Research and Academic Laboratories Mark et Revenue and Forecasts to 2027 (US$ Mn)
Figure 30. North America Hospitals Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 31. North America: RNAi Therapeutics Market, by Key Country - Revenue (2019) (USD Million)
Figure 32. North America RNAi Therapeutics Market Revenue and Forecast to 2027 (USD Million)
Figure 33. North America: RNAi Therapeutics Market, by Country, 2019 & 2027 (%)
Figure 34. US: RNAi Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
Figure 35. Canada: RNAi Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
Figure 36. Mexico: RNAi Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
Figure 37. Impact of COVID-19 Pandemic in North American Country Markets
Note: Product cover images may vary from those shown
  • Alnylam Pharmaceuticals, Inc
  • Arrowhead Pharmaceuticals, Inc
  • Quark
  • Rexahn Pharmaceuticals, Inc
  • Arbutus Biopharma
Note: Product cover images may vary from those shown
Adroll
adroll